End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43.3 CNY | -1.28% | +1.45% | +8.14% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.94 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.14% | 6.04B | C | ||
-32.21% | 15.27B | B- | ||
-31.97% | 10.84B | B | ||
-30.42% | 6.06B | B | ||
-11.41% | 5.86B | C+ | ||
-1.17% | 4.71B | D- | ||
+52.19% | 4.29B | - | C | |
-14.86% | 3.33B | C- | ||
-6.93% | 3.01B | C- | ||
-1.22% | 2.8B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603939 Stock
- Ratings Yifeng Pharmacy Chain Co., Ltd.